The 11 most recent market catalysts affecting $MNKD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 55
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald's reiteration of an Overweight rating and an $8 price target for MannKind signals continued analyst confidence in the company's financial health and future perfor…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind's partnership with Rose Pharma to develop an inhaled GLP-1 drug is a significant strategic move, positioning the company to enter the lucrative weight management market. W…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management
MannKind has licensed its proprietary Technosphere dry-powder inhalation technology to Rose Pharma for the development of ROSE-010, an investigational GLP-1 receptor agonist for we…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants
MannKind has filed an S-3 registration statement to allow certain selling stockholders to resell up to 12.85 million shares, including those from pre-funded warrants. This filing i…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on MannKind, signaling continued confidence in the company's long-term prospects. However, the price target w…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate
MannKind's Q2 earnings report presents a mixed bag for investors. While the company significantly missed EPS estimates, reporting a loss of $(0.01) per share compared to an expecte…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on MannKind and raised the price target from $11 to $14. This action signals increased confidence from a prom…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
Mannkind Corporation received FDA approval for Furoscix ReadyFlow, a novel autoinjector for edema in heart failure and chronic kidney disease patients. This is a major positive cat…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 95
MannKind shares are trading higher after the company announced it received FDA approval of its Furoscix ReadyFlow. Also, the company announced a $50 million private placement financing.
The FDA approval of Furoscix ReadyFlow is a major de-risking event for MannKind, validating its product pipeline and opening up new revenue streams. Coupled with the $50 million pr…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 65
MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24
MannKind Corporation announced a $50 million private placement financing with institutional investors, led by Frazier Life Sciences. This capital infusion is crucial as it provides…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 75
MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease
MannKind announced FDA approval for Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide for edema in heart failure and chronic kidney disease patients. This is a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.